Full Press Release Details
Lexaria Enters Investors Relations Contract with
KELOWNA, BC-- December 14, 2015 - Lexaria Corp. (OTCQB: LXRP)
(CNSX: LXX) (the "Company" or "Lexaria") has signed an Investor Relations and
media coverage services agreement with RADIUS Consulting, initially on a 45-day
trial basis, to provide services. RADIUS is a well known, New York-based firm
that has provided services to Nasdaq-listed and other firms.
RADIUS is a full-service investor relations firm leveraging 15
years experience providing strategic awareness across all investor mediums from
road show events to daily outreach targeting institutional, retail, and media
networks. RADIUS specializes in positioning small cap issuers for uplist to a
senior exchange across a diverse range of sectors including technology,
healthcare/life sciences, digital media, consumer/internet retail, natural
resources and financial services. For more information visit
Lexaria expects to receive media expertise as RADIUS will
leverage its full-spectrum media database comprised of print, television, and
online opinion leaders. Ongoing communication will be conducted as material
events are disseminated by the Company, since RADIUS clients are routinely
featured by major media outlets. RADIUS will also provide targeted daily retail
and institutional outreach and leverage its diverse finance providers, M&A
partners and knowledge of the uplisting process to ensure Lexaria is properly
positioned for long-term growth.
Lexaria is paying US$2,500 and issuing 50,000 restricted common
shares are being awarded as payment for the services. Services are to begin
Justin Kulik, Managing Partner of RADIUS, commented, In
evaluating early stage life science issuers with potential to achieve meaningful
long-term growth, we look for innovative technology, proven management and ripe
well-defined markets. Following our review and discussions with Lexaria
management we believe the Company is trending accordingly to build solid market
share in the New Year. We are excited to work closely with management on all
aspects of corporate communications and investor relations as the Company
continues to execute its growth strategy.
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The Company uses
innovative technology to deliver unique food experiences. www.lexarienergy.com
ViPovaTM uses only legal CBD oil extracts, grown
from agricultural hemp in locations where it is legal to do so, in
ViPovaTM-branded tea. ViPovaTM uses its patent-pending
process to infuse concentrated amounts of CBD within lipids in its tea,
providing more bioactivity and comfort to the body during the absorption
process. Only ViPovaTM has this ground-breaking technology for
CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: the
provision of any significant investor relations or media relations services.
Such forward-looking statements are estimates reflecting the Company's best
judgment based upon current information and involve a number of risks and
uncertainties, and there can be no assurance that other factors will not affect
the accuracy of such forward-looking statements. Access to capital, or lack
thereof, is a major risk and there is no assurance that the Company will be able
to raise required working capital. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that the
medical marijuana, hemp oil sector, or alternative health businesses will
provide any benefit to Lexaria, or that the Company will experience any growth
through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will not need to
attempt to raise additional capital. There is no assurance that any planned
corporate activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. There is no assurance that the cannabinoid/lipid
infusion technology will provide any increase in bioavailability to any
individual person. There is no assurance that any patent application in the USA
or any other nation or under any treaty will result in the award of an actual
patent; nor that an award of any actual patent will protect against challenges
from unknown third parties. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patent-pending technology will
in fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). ViPovaTM
products and Lexaria Energy products are not intended to diagnose, treat, cure
or prevent any disease.
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.